@article{PelzChuaEsquiveletal.2010,
  author    = {Pelz, Joerg O. W. and Chua, Terence C. and Esquivel, Jesus and Stojadinovic, Alexander and Doerfer, Joerg and Morris, David L. and Maeder, Uwe and Germer, Christoph-Thomas and Kerscher, Alexander G.},
  title     = {Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-67875},
  year      = {2010},
  abstract  = {Background: We evaluate the long-term survival of patients with peritoneal carcinomatosis (PC) treated with systemic chemotherapy regimens, and the impact of the of the retrospective peritoneal disease severity score (PSDSS) on outcomes. Methods: One hundred sixty-seven consecutive patients treated with PC from colorectal cancer between years 1987-2006 were identified from a prospective institutional database. These patients either received no chemotherapy, 5-FU/Leucovorin or Oxaliplatin/Irinotecan-based chemotherapy. Stratification was made according to the retrospective PSDSS that classifies PC patients based on clinically relevant factors. Survival analysis was performed using the Kaplan-Meier method and comparison with the log-rank test. Results: Median survival was 5 months (95\% CI, 3-7 months) for patients who had no chemotherapy, 11 months (95\% CI, 6-9 months) for patients treated with 5 FU/LV, and 12 months (95\% CI, 4-20 months) for patients treated with Oxaliplatin/Irinotecan-based chemotherapy. Survival differed between patients treated with chemotherapy compared to those patients who did not receive chemotherapy (p = 0.026). PSDSS staging was identified as an independent predictor for survival on multivariate analysis [RR 2.8 (95\%CI 1.5-5.4); p < 0.001]. Conclusion: A trend towards improved outcomes is demonstrated from treatment of patients with PC from colorectal cancer using modern systemic chemotherapy. The PSDSS appears to be a useful tool in patient selection and prognostication in PC of colorectal origin.},
  subject      = {Krebs <Medizin>},
  language  = {en}
}
@article{DuhrKennKickuthetal.2011,
  author    = {Duhr, Carolin D. and Kenn, Werner and Kickuth, Ralph and Kerscher, Alexander G. and Germer, Christoph-Thomas and Hahn, Dietbert and Pelz, Joerg O. W.},
  title     = {Optimizing of preoperative computed tomography for diagnosis in patients with peritoneal carcinomatosis},
  series = {World Journal of Surgical Oncology},
  volume    = {9},
  journal   = {World Journal of Surgical Oncology},
  number    = {171},
  doi       = {10.1186/1477-7819-9-171},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-138024},
  year      = {2011},
  abstract  = {Background and Objective This study evaluates whether Computer Tomography is an effective procedure for preoperative staging of patients with Peritoneal Carcinomatosis. Method A sample of 37 patients was analyzed with contrast enhanced abdominal Computer Tomography, followed by surgical staging. All Computer Tomography scans were evaluated 3 times by 2 radiologists with one radiologist reviewing 2 times. The efficacy of Computer Tomography was evaluated using the Spearman correlation coefficient. Correlations were analyzed by abdominopelvic region to assess results of the Peritoneal Carcinomatosis Index (PCI) aggregating the 13 regions. Surgical findings were compared to radiological findings. Results Results indicate high correlations between the surgical and radiological Peritoneal Carcinomatosis Indices. Analyses of the intra-class correlation between the first and second reading of one radiologist suggest high intra-observer reliability. Correlations by abdominopelvic region show higher values in the upper and middle regions and relatively lower values in the lower regions and the small bowel (correlation coefficients range between 0.418 and 0.726, p < 0.010; sensitivities range between 50\% and 96\%; and specificities range between 62\% and 100\%). Conclusion Computer Tomography represents an effective procedure in the preoperative staging of patients with PC. However, results by abdominopelvic region show lower correlation, therefore suggest lower efficacy. These results are supported by analyses of sensitivity and accuracy by lesion size. This suggests that Computer Tomography is an effective procedure for pre-operative staging but less for determining a tumor's accurate extent.},
  language  = {en}
}
@article{SeyfriedvonRahdenMirasetal.2015,
  author    = {Seyfried, Florian and von Rahden, Burkhard H. and Miras, Alexander D. and Gasser, Martin and Maeder, Uwe and Kunzmann, Volker and Germer, Christoph-Thomas and Pelz, J{\"o}rg O. W. and Kerscher, Alexander G.},
  title     = {Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin - a longitudinal experience from a prospectively collected database of 1108 patients},
  series = {BMC Cancer},
  volume    = {15},
  journal   = {BMC Cancer},
  number    = {73},
  doi       = {10.1186/s12885-015-1081-8},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-125014},
  year      = {2015},
  abstract  = {Background Comprehensive evidence on the incidence, time course and independent risk factors of metachronous peritoneal carcinomatosis (metaPC) in gastric cancer patients treated with curative intent in the context of available systemic combination chemotherapies is lacking. Methods Data from a prospectively collected single-institutional Center Cancer Registry with 1108 consecutive patients with gastric adenocarcinoma (GC), clinical, histological and survival data were analyzed for independent risk factors and prognosis with focus on the development of metaPC. Findings were then stratified to the time periods of treatment with surgery alone, 5-Fluorouracil-only and contemporary combined systemic perioperative chemotherapy strategies, respectively. Results Despite R0 D2 gastrectomy (n = 560), 49.6\% (±5.4\%) of the patients were diagnosed with tumour recurrence and 15.5\% (±1.8\%) developed metaPC after a median time of 17.7 (15.1-20.3) months after surgery resulting in a tumour related mortality of 100\% with a median survival of 3.0 months (2.1 - 4.0). Independent risk factors for the development of metaPC were serosa positive T-category, nodal positive-status, signet cell and undifferentiated gradings (G3/G4). Contemporary systemic combination chemotherapy did not improve the incidence and prognosis of metaPC (p = 0.54). Conclusions Despite significant improvements in the overall survival for the complete cohort with gastric cancer over time, those patients with metaPC did not experience the same benefits. The lack of change in the incidence, and persistent poor prognosis of metaPC after curative surgery expose the need for further prevention and/or improved treatment options for this devastating condition.},
  language  = {en}
}